Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lisa Zimmer, Florentia Dimitriou, Piyush Grover, Jessica Cecile Hassel, Michael Erdmann, Andrea Forschner, Douglas Buckner Johnson, Elisabeth Livingstone, Alexander Roesch, Selma Ugurel, Carsten Schulz, Carola Berking, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Dirk Schadendorf, Lea Jessica Albrecht
Institutions: Essen University Hospital, University Hospital Zurich, Melanoma Institute Australia, University Hospital Heidelberg, National Center for Tumor Diseases, Universitätsklinikum Erlangen, Universitätsklinikum Tübingen, Vanderbilt University Medical Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen, The University of Sydney, University of Zurich, Stiftung Universitätsmedizin Essen
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4379280610